October 16, 2020
Chugai Pharmaceutical said on October 15 that it has filed a new drug application in Japan for risdiplam, an oral survival motor neuron-2 (SMN2) splicing modifier, for the treatment of spinal muscular atrophy (SMA). It will be the first oral...read more